CytomX Therapeutics, Inc. financial data

Symbol
CTMX on Nasdaq
Industry
Pharmaceutical Preparations
Location
151 Oyster Point Blvd., Suite 400, South San Francisco, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 118 % -20.1%
Debt-to-equity -575 % -53%
Return On Equity -27.4 % -155%
Return On Assets 5.78 %
Operating Margin 4.79 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 78.1M shares +17%
Common Stock, Shares, Outstanding 67.3M shares +1.64%
Entity Public Float 114M USD -3.63%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 84.9M shares +27.6%
Weighted Average Number of Shares Outstanding, Diluted 84.9M shares +27.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 120M USD +50.4%
Revenue from Contract with Customer, Excluding Assessed Tax 120M USD +50.4%
Research and Development Expense 83.1M USD -9.5%
General and Administrative Expense 30.8M USD -14.3%
Operating Income (Loss) 5.72M USD -152%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 15.1M USD -496%
Income Tax Expense (Benefit) 3.99M USD
Net Income (Loss) Attributable to Parent 11.1M USD -501%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 43.2M USD -24.8%
Cash, Cash Equivalents, and Short-term Investments 138M USD -24.2%
Accounts Receivable, after Allowance for Credit Loss, Current 2.78M USD +45.8%
Assets, Current 143M USD -23.8%
Property, Plant and Equipment, Net 3.32M USD -26.3%
Operating Lease, Right-of-Use Asset 10.2M USD -27.6%
Goodwill 949K USD 0%
Other Assets, Noncurrent 76K USD -16.5%
Assets 159M USD -23.9%
Accounts Payable, Current 611K USD -40.6%
Employee-related Liabilities, Current 5.74M USD +5.42%
Accrued Liabilities, Current 13.6M USD -32.1%
Contract with Customer, Liability, Current 124M USD +2.9%
Liabilities, Current 143M USD +1.05%
Contract with Customer, Liability, Noncurrent 36.7M USD -73.9%
Operating Lease, Liability, Noncurrent 6.89M USD -41.4%
Other Liabilities, Noncurrent 3.99M USD +1749%
Liabilities 190M USD -35.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4K USD -111%
Retained Earnings (Accumulated Deficit) -716M USD +1.52%
Stockholders' Equity Attributable to Parent -31.2M USD +63.3%
Liabilities and Equity 159M USD -23.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -26M USD -379%
Net Cash Provided by (Used in) Financing Activities 174K USD
Net Cash Provided by (Used in) Investing Activities 44.9M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 67.3M shares +1.64%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 175M USD +5.67%
Deferred Tax Assets, Gross 179M USD +5.41%
Operating Lease, Liability 14M USD -22.6%
Payments to Acquire Property, Plant, and Equipment 115K USD +140%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 11M USD -506%
Lessee, Operating Lease, Liability, to be Paid 15.7M USD -25.7%
Property, Plant and Equipment, Gross 18.6M USD -4.11%
Operating Lease, Liability, Current 4.86M USD +12.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.73M USD +2.82%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.57M USD +2.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.71M USD -43.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.39M USD -23.4%
Deferred Tax Assets, Operating Loss Carryforwards 56.8M USD -2.45%
Unrecognized Tax Benefits 19.4M USD +109%
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.39M USD -23.4%
Additional Paid in Capital 685M USD +6.66%
Amortization of Intangible Assets 36K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 3.36M USD -6.57%
Share-based Payment Arrangement, Expense 14.6M USD +6.19%